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1016 ABSTRACTSLPLase, but nevertheless it interacts with known inhibitors
of eosinophil LPLase via amino acid residues in its CRD.
The enzyme responsible for human eosinophil LPLase
activity remains to be been defined, but may be similar to
pancreatic LPLase (12).
The galectins comprise a growing family of animal lectins
which possess at least one CRD, and exhibit some sequence
conservation (13). Members of this family show a wide-
spread distribution across genus and species, ranging from
sponges to humans, and have been implicated in intra- and
extracellular functions such as cell–cell and cell–matrix
interactions through glycoconjugate-mediated recognition.
To date, 10 mammalian galectins including CLC protein
have been identified, as well as many from other genera and
species (6). Galectins 7 and 10 are the only monomeric
members of the galectin family for which crystal structures
have been determined (3,8). As noted above, the overall
structural fold of Galectin-10 is highly similar to that of
Galectin-7. However, their CRDs are quite different with
only nine out of the 13 residues which comprise the CRD
conserved between these two galectins. These differences
cause significant changes both in the topology and chemical
nature of their CRDs, and have implications for both their
carbohydrate ligand specificities and precise biological
function(s). The crystal liganded structures of Galectin-7
and Galectin-10 have provided new insights into the
multivalent functionality of the galectin family in carbohy-
drate recognition. In particular, Galectin-7 binds lacto-
samine-containing simple saccharides but not mannose in
the crystal, in marked contrast to Galectin-10 (CLC
protein) which fails to bind lactosamine-containing sugars,
but instead binds mannose via a different structural
mechanism (Fig. 1) (7). The ability of CLC protein to bind
mannose draws attention to the functional activities of the
family of mannose-binding proteins. These proteins are
generally C-type lectins, which include serum mannose-
binding proteins and pulmonary surfactant apoproteins A
and D. Mannose-binding proteins play a role in antibody-
independent host defense against pathogens by binding
avidly to carbohydrate structures on foreign cell surfaces
and inducing opsonization and complement-mediated cell
lysis. Although CLC protein shares no apparent sequence
homology with the mannose-binding proteins, it could play
a similar role in eosinophil effector or inflammatory
responses to multicellular (helminth) parasites. Although
we have shown that CLC protein binds mannose, the
natural glycoconjugate ligand of the protein has yet to be
identified. Our results provide a starting point in the search
for the biologically relevant ligand(s) of CLC protein, as
well as in providing clues to its functional role(s) in
eosinophils and basophils.
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Uppsala, SwedenThe use of eosinophil granule proteins as markers of
eosinophil activity and turnover in human disease was
suggested in the mid 1970s. The commercialization of
immuno-assays to measure one of these proteins, i.e. ECP
(eosinophil cationic protein), has made this a common tool
in research and as a clinical tool in the monitoring
of certain patients with asthma, atopic dermatitis, food
allergy etc.
The eosinophil markers have been measured in most
body fluids as reflections of the activity of the eosinophils in
the local process or as reflections of systemic activation of
the cells (1). Measurements in local fluids involve the
cerebrospinal fluid in patients with various neurological
disorders. Thus, highly raised levels of ECP were observed
in patients with bacterial meningitis (2), but also to some
extent in viral encephalitis and in multiple sclerosis
indicating the involvement of the eosinophils in the
inflammatory processes in these diseases. The levels in
bacterial meningitis were of particular interest, since the
highest levels were found in those patients who had a poor
outcome of their disease. The levels were in fact well above
or equal to the levels needed to induce permanent
neurological damage in experimental animals (3). The
measurements were performed in nasal washings in
patients with nasal disorders, in particular in rhinitis, but
also as tools to monitor environmental influences
ABSTRACTS 1017on the nasal mucosa (4). In the latter case high levels of
ECP were found in school personel working in poorly
ventilated schools. In the middle ear fluid ECP and
EPO (eosinophil peroxidase) were measured as indicators
of the involvement of eosinophils in chronic otitis
media with effusion (5) possibly an indication of the
allergic origin of this disease in many cases. The measure-
ment bronchial and bronchoalveolar lavage fluids in
patients with various pulmonary diseases such as asthma,
ARDS (adult respiratory distress syndrome) and idiopathic
pulmonary fibrosis (6) indicated the involvement of
eosinophils in all these diseases, since raised levels and
significant correlations to other measures of disease activity
were obtained. For practical clinical purposes the measure-
ment of ECP and EPO in spontaneous or induced sputum
has attracted a lot of interest and shown elevated levels in
asthma and asthma-like syndromes (7), but also in some
patients with chronic obstructive pulmonary disease
(COPD) (8). Moreover, ECP and EPX (eosinophil protein
x) were measured in the urine as indicators of local
processes, but also, in the case of EPX, as a monitoring
tool of the systemic activation of eosinophils. These
proteins were also measured in perfusion fluids of the small
intestine and colon and clearly indicated the involvement of
eosinophils in inflammatory bowel disease and the celiac
disease (9,10). Measurements in faeces were also performed
in these disorders and showed elevated levels. Highly
elevated levels of ECP were measured in tear fluids in
patients with conjunctivitis of different aetiologies (11) and
in skin window fluids in patients with skin diseases such as
psoriasis and eczema (12).
Most popular, however, is the measurement of the
eosinophil granule proteins, i.e. ECP, in blood and in
particular in serum. The serum levels of ECP reflect the
activity of the circulating eosinophils, but will, in cases
with no alterations in the activity of the eosinophils,
reflect the size of the circulating population (13). The
release of ECP from the eosinophils is an active process
and continues after the blood has been drawn unless
inhibitors, such as EDTA, have been added. Thus, the
measurement in serum is the result of in vivo release and ex
vivo release of ECP and in most cases the ex vivo release is
the dominant contribution. From this knowledge it follows
that a strict standardization of the blood sampling
procedure as to time, temperature and blood sampling
vessels is necessary in order to obtain reproducible results.
Differences in these procedures are illustrated by the large
differences in published normal serum levels of ECP. In fact
these vary about 10-fold in spite of the fact that the same
immunoassay was used. In spite of these diculties a great
number of publications have shown that the serum
measurements of eosinophil granule proteins provide
interesting and clinically useful information as to the
activity of the eosinophil population. This fact is illustrated
by three recent multicenter studies, which all showed that
the levels of ECP were superior tools in the therapy
monitoring of inhaled glucocorticosteroids and in the
prediction of asthma.References
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